Compare VNDA & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNDA | SLP |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.4M | 367.9M |
| IPO Year | 2005 | 1996 |
| Metric | VNDA | SLP |
|---|---|---|
| Price | $5.39 | $18.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $14.90 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 858.1K | 692.5K |
| Earning Date | 05-06-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | ★ $216,105,000.00 | $59,577,000.00 |
| Revenue This Year | $21.35 | $3.80 |
| Revenue Next Year | $37.40 | $5.90 |
| P/E Ratio | ★ N/A | $42.41 |
| Revenue Growth | 8.72 | ★ 10.52 |
| 52 Week Low | $4.14 | $11.09 |
| 52 Week High | $9.91 | $21.01 |
| Indicator | VNDA | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 32.43 | 63.01 |
| Support Level | $5.11 | $17.74 |
| Resistance Level | $5.58 | $18.62 |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | -0.07 | -0.12 |
| Stochastic Oscillator | 8.61 | 14.42 |
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.